Wyeth secures Australian injunction against MSD vaccine
30-11-2020
MSD secures victory before English court
20-10-2020
Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29-09-2020
Katherine Welles / Shutterstock.com
In a mixed decision for Merck Sharp Dohme (MSD), the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
MSD, Merck Sharp Dohme, Wyeth, Pfizer, vaccine, patent infringement, patent invalidity
